Standardised rate of measles hospitalizations per 100,000 inhabitants, by region

<p><b>Copyright information:</b></p><p>Taken from "Health burden and economic impact of measles-related hospitalizations in Italy in 2002–2003"</p><p>http://www.biomedcentral.com/1471-2458/7/169</p><p>BMC Public Health 2007;7():169-169.</p><p>Published online 24 Jul 2007</p><p>PMCID:PMC1963450.</p><p></p> Italy 2002 and 2003

Rate ratio of sudden unexpected deaths in infants of age 31–729 days by risk period (following any vaccination) and dose, Italy 1999–2004.

<p>N: Number of deaths; RR adj: adjusted Rate Ratio; CI: Confidence Interval.</p>1<p>RRs are estimated according to the self controlled case-series method for censoring, perturbed or curtailed post-event exposures <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0016363#pone.0016363-Farrington3" target="_blank">[19]</a> and adjusted by age group (31–80; 81–100; 101–120; 121–180; 181–360; 361–729).</p

Rate ratio of sudden unexpected deaths in infants of age 31–729 days by risk period and type of vaccine, Italy 1999–2004.

<p>N: Number of deaths; P-d: Person-days at risk; RR adj: adjusted Rate Ratio; CI: Confidence Interval.</p>1<p>RRs are estimated by the Poisson regression model and adjusted by age group (31–80; 81–100; 101–120; 121–180; 181–360; 361–729).</p>2<p>The information of the brand name of the hexavalent product was missing for 1 infant (the event occurred in the control period).</p

Rate ratio of sudden unexpected deaths in infants of age 31–729 days for the risk period 0–14 days following vaccination with a combination of six antigens by dose, Italy 1999–2004.

<p>N: Number of deaths; P-d: Person-days at risk; RR adj: adjusted Rate Ratio; CI: Confidence Interval.</p>1<p>RRs are estimated by the Poisson regression model and adjusted by age group (31–80; 81–100; 101–120; 121–180; 181–360; 361–729 for the first dose; 31–180; 181–360; 361–729 for the second-third dose).</p>2<p>The information on the brand name of the hexavalent product was missing for 1 infant (the event occurred in the control period).</p

Distribution of immunised subjects by interval between date of vaccination and date of death.

<p>* Legend. *Only events occurring within 45 days from vaccination are shown.</p

Selection of the study population, age 31–729 days, Italy 1999–2004.

<p>Legend. *One subject was excluded because the date of birth was unknown.</p

Description of the observation period for a hypothetical subject included in the study.

<p>Legend A. Self-controlled case-series method for censoring, perturbed or curtailed post-event exposures <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0016363#pone.0016363-Farrington3" target="_blank">[19]</a> Legend B. Poisson regression model.</p

Distribution of the 604 events of SUD included in the study by age of death.

<p>Legend. The three arrows indicate the median age at first, second and third vaccine dose.</p

Distribution of the 244 immunised subjects by vaccine dose.

<p>MMR: measles-mumps-rubella vaccine.</p

Characteristics of GBS cases by vaccine brand, n. 287 (27 December 2020–30 September 2021).

Characteristics of GBS cases by vaccine brand, n. 287 (27 December 2020–30 September 2021).</p